Hundreds of genetically characterized cell lines are available for the discovery of genotype-specific cancer vulnerabilities. However, screening large numbers of compounds against large numbers of cell lines is currently impractical, and such experiments are often difficult to control [1] [2] [3] [4] . Here we report a method called PRISM that allows pooled screening of mixtures of cancer cell lines by labeling each cell line with 24-nucleotide barcodes. PRISM revealed the expected patterns of cell killing seen in conventional (unpooled) assays. In a screen of 102 cell lines across 8,400 compounds, PRISM led to the identification of BRD-7880 as a potent and highly specific inhibitor of aurora kinases B and C. Cell line pools also efficiently formed tumors as xenografts, and PRISM recapitulated the expected pattern of erlotinib sensitivity in vivo.
Cell lines have long served as tools for oncology drug discovery 5 . Their track record in predicting efficacy in patients, however, has been mixed. Cell line models often have been chosen more for their tractability than for their reflection of genetic diversity across human cancers. It is not surprising that generalizations from studies of few cell lines have met with limited success. With the ability to comprehensively characterize the genomes of tumors has come the recognition that the varied responses of patients to treatment are largely explained by the genetic diversity of cancer. Recent reports show that this diversity is reflected in established cell lines 3 . Although it is possible to profile the activity of compounds across large numbers of cell lines and then correlate response to specific genetic features 3, 4, 6, 7 , profiling drugs across large numbers of cell lines is often intractable because of the time and resources involved.
We hypothesized that the challenge of profiling hundreds of cell lines might be addressed by a pooled approach. Assaying cell lines in pools has the theoretical advantages of (i) increasing throughput and (ii) allowing for internally controlled experiments (whereby each cell in a pool is exposed to identical drug concentrations and culture conditions). Although cell-cell interactions or paracrine effects of different cell lines growing in a pool could, in principle, confound patterns of drug sensitivity observed in cell lines cultured alone, we reasoned that such concerns would be outweighed by the throughput advantage of a pooled approach. We also note that in vivo, tumors grow not as uniform masses of cells but rather as complex mixtures of genetically diverse tumor cells 8 and nonmalignant cells of the tumor microenvironment.
To deconvolute pools of cancer cell lines, we used molecular barcoding because of the nearly limitless number of barcodes and the availability of a flexible, high-throughput (500-plex) barcode detection system based on Luminex microspheres, which have been used in multiplexed assays of gene expression 9 and protein phosphorylation 10 , and in genetic screens of PI3-kinase inhibitor activity 11 .
We designed the PRISM assay using lentiviral vectors that permitted stable integration of 24-base-pair DNA barcode sequences engineered to have limited sequence homology to the human genome. Common primer sites flanking the barcode sequence allowed for amplification of barcodes with a single set of primers (including one biotinylated primer). We hybridized the amplicons to Luminex microspheres of distinct colors (each coupled to a different anti-barcode oligonucleotide) and stained with phycoerythrin-streptavidin. We quantified hybridization events on a Luminex detector, wherein the bead color denotes the barcode identity, and the phycoerythrin intensity reveals barcode abundance, a direct reflection of cell number ( Fig. 1) .
To establish feasibility and determine the sensitivity of PRISM, we analyzed five barcoded adenocarcinoma cell lines. We plated 1,000 cells each of four barcoded lines as a mixture and added the fifth line in varying number. The following day, we collected genomic DNA from the mixtures, and detected the barcodes. As predicted, the four invariant lines showed similar signals in all mixtures, whereas the High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines l e t t e r s varied fifth line gave a signal directly proportional to cell number ( Fig. 2a) . The assay was highly sensitive, enabling detection of as few as 10 cells in a mixture of 4,000 (i.e., <0.5% of the total cell number).
We next treated a pool of 25 lung adenocarcinoma cell lines with compounds known to have genotype-specific patterns of killing. To account for different doubling times of cell lines, we compared each compound-treated cell line to vehicle-treated controls to compute the relative growth inhibition of each line. Whereas treatment with puromycin resulted in uniform killing across the pool (Fig. 2b) , treatment with the EGFR inhibitor erlotinib (Tarceva) resulted in the dose-dependent killing of the four EGFR-mutant cell lines in the pool, concordant with previous studies 2 ( Fig. 2b and Supplementary  Fig. 1) . Similarly, we observed another expected pattern of cell killing 12 with the ALK kinase inhibitor NVP-TAE-684 ( Fig. 2b) : the NCI-H3122 cell line, harboring an EML4-ALK translocation, was sensitive to the drug, whereas NCI-H2228, with a different EML4-ALK translocation, exhibited intrinsic resistance.
To test whether PRISM can recapitulate the results observed in traditional cell line experiments, we created a panel of 100 barcoded cell lines comprising 18 lineages and challenged these in four pools of 25 cell lines with each of 43 anticancer compounds (including both targeted and cytotoxic agents), yielding 3,200 measurements per compound ( Supplementary Table 1 ). We saw no evidence of PRISM performance varying as a function of tumor type or cell lineage, although larger panels of cell lines would be required to exclude this definitively. As expected, PRISM revealed similar patterns of activity across the 100 lines among functionally related compounds (e.g., microtubule binders, topoisomerase inhibitors or MEK inhibitors; Supplementary Fig. 2a ). For 23 compounds, we had access to sensitivity data across the same 100 cell lines measured by others in individual cell line assays measuring either ATP content (using CellTiter-Glo) or enumeration of cell nuclei (using an optical fluorescent imaging method, Opera) 3, 13 .
Using area under the curve (AUC) as a measure, the traditional ATP content and number of nuclei (below referred as 'nuclei') readouts yielded similar global patterns of sensitivity (Pearson r = 0.80, P < 0.0001). PRISM yielded similar levels of global correlation (r = 0.72 compared to nuclei, P < 0.0001; r = 0.66 compared to ATP, P < 0.0001) ( Fig. 2c and Supplementary Table 2 ). We note that the slightly stronger correlation between PRISM and nuclei data is expected because PRISM and nuclei are both direct readouts of cell number, whereas ATP measurement reflects a combination of cell number and metabolic activity.
For example, PRISM and nuclei similarly identified hypersensitivity of BRAF-mutant melanoma cell lines to the BRAF inhibitor PLX4720 (Supplementary Fig. 2b ). We saw no significant differential sensitivity (two-tailed t-test, P > 0.05) to the RAF inhibitor sorafenib (Nexavar), now known to be only a weak inhibitor of the BRAF kinase 1, 14 (Supplementary Fig. 2b) . Similarly, PRISM detected a trend (P = 0.054) between BRAF mutation and sensitivity to the MEK inhibitor AZD6244 (acting immediately downstream of BRAF), findings consistent with clinical activity in patients with BRAF-mutant melanoma 15 (Supplementary Fig. 2b ). PRISM and traditional methods yielded concordant results for 21/23 of compounds tested (91%), but two drugs (topotecan (Hycamtin) and paclitaxel (Taxol)) showed slightly discordant results ( Supplementary Fig. 3 ). Whether these exceptions arise from the 3-d (nuclei) versus 5-d (PRISM) assay periods remains to be determined.
We next asked whether the PRISM approach could be extended to the in vivo setting, where the ability to multiplex cell lines in a single xenotransplant might accelerate translational research. One theoretical concern was that a small number of cell lines within a pool might rapidly overtake the others in vivo. To test this, we injected a pool of 24 barcoded lung adenocarcinoma cell lines subcutaneously into each of ten recipient NSG (NOD-SCID-IL2Rgamma null ) mice. Several weeks later, we euthanized the mice and resected the tumors. PRISM detected 23/24 cell lines (96%) in each of ten vehicle-treated mouse tumors. The 23 detectable lines grew at different rates, but their relative abundances within the tumors were nearly identical across the ten vehicle-treated xenografts (Fig. 2d) . Similarly, we sampled four different portions of each tumor, and found little variation in the contribution of particular cell lines in different parts of the tumor (e.g., Supplementary Fig. 4 ). We also passaged an aliquot of the initial mixture of cell lines used for injection in vitro weekly for 3 months. As with the in vivo experiments, the vast majority of the initial cell lines were detectable after 98 d in culture, and the abundance of each line remained stable over time (Supplementary Fig. 5 ). These results Barcode sequences are amplified using PCR and universal primers (one of which is biotinylated), and amplified sequences are hybridized to individual microbeads harboring antisense barcode sequences and then to streptavidin-phycoerythrin. A Luminex FlexMap detector quantitates fluorescence signal for each bead. To adjust for differing barcoding efficiencies and differing cell doubling, the signal for each barcoded cell line is scaled to that of vehicle-treated control, thus demonstrating relative inhibition profiles for specific test compounds across multiple cell lines in mixture.
npg l e t t e r s suggest that despite differences in growth rates, cell mixtures may reach an equilibrium state.
Next, we investigated whether PRISM could detect the expected sensitivity of EGFR-mutant cell lines when treated with erlotinib in vivo. We treated cohorts of ten mice daily for 16 d by gavage with erlotinib versus vehicle. Erlotinib treatment caused a marked reduction in relative abundance of 4/4 EGFR-mutant lines (by 22%, 88%, 75% and 76%), whereas the 15/19 detectable wild-type EGFR lines were either minimally affected or increased in proportional abundance ( Fig. 2d) . As a group, mutant EGFR lines were significantly different from wild-type EGFR lines (Kolmogorov-Smirnov D = 0.84, P = 0.0079; Fig. 2e) . Notably, the EGFR-mutant line showing the smallest in vivo response to erlotinib (HCC2935) was also less sensitive to erlotinib in vitro (cf. Fig. 2b) . These experiments demonstrate the feasibility of PRISM to assess drug sensitivity in vivo.
We next examined whether PRISM could be used not only to elucidate the differential cytotoxic activity of optimized compounds (drugs) but also to discover new anticancer agents. We tested 102 barcoded lines (90 non-small cell lung adenocarcinoma (NSCLC) lines plus 12 lines of other lineages; Supplementary Table 2 ). The 102 cell lines, assayed in four pools of 25-27 cell lines, were screened against a library of 8,000 small molecules created using diversity-oriented synthesis (DOS) [16] [17] [18] and 400 tool compounds or oncology drugs with known mechanism of action 19 .
This large data set allowed systematic evaluation of the PRISM assay performance. Nearly all of the 102 cell lines yielded sufficient signal for drug sensitivity analysis (strictly standardized mean difference 20 ; Supplementary Figs. 6 and 7) , despite a more than tenfold signal range across the panel at baseline ( Supplementary  Fig. 6c ). Although the determinants of cell line signal are likely multifactorial, we observed a correlation with proliferation rate (Supplementary Fig. 6d ), suggesting that future assays could benefit from pooling based on cell doubling times.
As expected, many of the oncology drugs and optimized tool compounds displayed activity against cell lines ( Supplementary Table 3 and Supplementary Fig. 7) . Furthermore, compounds with the same mechanism of action displayed markedly similar activity profiles across the cell line panel (Supplementary Fig. 8) . Similarly, cell lines labeled with different barcodes and assayed in different pools showed similar patterns of compound activity, again reflecting robustness of PRISM ( Supplementary Fig. 9 and Supplementary Table 3 ).
This large data set also allowed us to assess the ability of PRISM to reveal genotype-phenotype relationships. We observed expected relationships between drug sensitivity and molecular features of the cell lines (from the Cancer Cell Line Encyclopedia 13 , Mycoplasma-negative lines with authentication data in Supplementary Table 4 ) in genomewide analyses ( Supplementary Table 5 ). For example, sensitivity to nutlin-3 (designated BRD-A12230535), an inhibitor of the MDM2-TP53 interaction, was most strongly inversely correlated to expression of the gene encoding MDM2 (Spearman r = −0.66, P < 10 −5 ). Erlotinib sensitivity demonstrated a strong inverse correlation with both EGFR gene expression (r = −0.61, P < 10 −5 ) and EGFR gene copy number NCI-H522  HCC1359  NCI-H2009   EKVX  HCC461  A549  NCI-H1792   Calu-1  NCI-H23  HCC95  NCI-H647  NCI-H2077  HCC1171  NCI-H1568   Calu-6  NCI-H2052  LCLC103H  NCI-H2887  HCC366  NCI-H2228  NCI-H3122  HCC827  HCC2279  HCC2935 PC l e t t e r s (r = −0.52, P = 2 × 10 −5 ). Sensitivity to gefitinib (Iressa, another EGFR inhibitor) showed similar correlations to EGFR gene expression and copy number (r = −0.51, P < 10 −6 and r = −0.54, P < 10 −6 , respectively). These results suggest that beyond the well-recognized effect of EGFR mutation on conferring EGFR inhibitor sensitivity, EGFR expression and copy number may represent subtle determinants of sensitivity that are only revealed when large panels of cell lines are examined. As a community resource, gene expression and copy number correlates to sensitivity of the 370 reference compounds that showed PRISM activity are shown in Supplementary Table 5 .
We next turned to the results of the 8,000 DOS compounds screened against 102 cell lines. One 199 of the DOS compounds (2.5%) scored as hits in the primary screen (defined as at least one cell line being inhibited > 80% relative to control) and 139/199 (69.8%) compounds validated in a 8-point PRISM dose-response assay ( Supplementary  Table 6 ). Of the 139 compounds, 49 (24.5%) killed >70% of the cell lines, suggesting that they were nonspecific cytotoxic agents. One of the 90 selective compounds, we examined BRD-7880 in detail.
First, we asked whether the PRISM sensitivity profile across 102 cell lines could be used to gain insight into BRD-7880's mechanism of action by comparing its sensitivity profile to those of 400 tool compounds profiled in these same lines. BRD-7880 showed markedly similar activity to the aurora kinase inhibitor tozasertib (VX-680; Spearman r = 0.77, Fig. 3a,b and Supplementary Table 7) , suggesting that despite the lack of structural similarity between the two compounds ( Fig. 3c) , BRD-7880 might be an aurora kinase inhibitor. Treatment of HCT-116 cells with BRD-7880 resulted in polyploidy (Supplementary Fig. 10a ) and decreased phosphorylation of serine 10 in histone H3 (Supplementary Fig. 10b ), supporting its functioning as an inhibitor of aurora kinase B (AURKB) [21] [22] [23] .
Biochemical kinase activity assays showed that BRD-7880 is a potent inhibitor of AURKB and AURKC (half-maximal inhibitory concentration (IC 50 ) of 7 nM and 12 nM, respectively) with less activity against AURKA (IC 50 = 2,153 nM) (Fig. 3d) , a profile resembling that of barasertib (AZD1152-HQPA; Supplementary Fig. 11 ). Kinetic measurements of in vitro AURKB activity suggested that BRD-7880 functions in an ATP-competitive manner (Supplementary Fig. 12) .
To assess the specificity of BRD-7880, we profiled kinase activity for 308 kinases, and this analysis showed that BRD-7880 is far more selective than tozasertib, substantially inhibiting (to <25% control activity) only AURKB and AURKC (Supplementary Table 8) . Similarly, in a screen of kinase-binding selectivity across 98 kinases BRD-7880 showed highly specific binding to AURKB and AURKC ( Fig. 3e and  Supplementary Table 9 ). We are unaware of any other aurora kinase 
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Tozasertib Table 9 ); green circles represent tested kinases for which BRD-7880 decreases binding <75% control. Published relative affinities of tozasertib (VX-680) for same 98 kinases (where available 24, 25 ) (right). l e t t e r s inhibitor with this degree of specificity. The result also demonstrates the utility of PRISM for rapidly identifying a molecular target: the target of BRD-7880 was revealed simply by virtue of its pattern of activity across a large panel of cell lines. Such activity would not have been obvious had the compound been tested on only a small number of cell lines. PRISM will facilitate oncology drug discovery by making it feasible to rapidly test chemical analogs across an entire cell line panel, thus assuring that the expected on-target pattern of activity is retained. The facile expansion of a single vial of pooled, barcoded cells provides a practical solution for extending traditional compound screening to hundreds of individual cell lines. Furthermore, our demonstration of the feasibility of using PRISM in vivo suggests that cost-effective xenograft studies are possible. The bead-based barcode quantitation method used here has proven reliable and inexpensive, but further cost reductions will likely be achievable with massively parallel sequencing.
PRISM may facilitate cancer therapeutic discovery. Entire smallmolecule libraries could be screened across large panels of cell lines, and compounds selected for their differential killing (e.g., selectively killing cells harboring 'undruggable' targets). We believe that the cancer research community would benefit from the creation of thousands of genetically characterized, barcoded cell lines. With such a resource, large-scale testing of compounds across the diversity of human cancer types could become a routine activity.
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